A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Conditions
AML (Acute Myelogenous Leukemia) · Acute Lymphoid Leukemia (ALL) · Acute Leukemia (Category) · MDS (Myelodysplastic Syndrome) · CML (Chronic Myelogenous Leukemia) · CLL (Chronic Lymphocytic Leukemia) · Prolymphocyctic Leukemia · Chronic Myelomonocytic Leukemia (CMML) · Myeloproliferative Neoplasm (MPN) · Lymphoma · Myelofibrosis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Alabama Birmingham, Birmingham, Alabama, United States
City of Hope, Duarte, California, United States
Stanford, Palo Alto, California, United States
University of Miami, Miami, Florida, United States
University of Kansas Medical Center, Westwood, Kansas, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
Memorial Sloan Kettering, New York, New York, United States
University of North Carolina, Chapel Hill, North Carolina, United States
Oregon Health & Science University, Portland, Oregon, United States
MD Anderson, Houston, Texas, United States
University of Virginia, Charlottesville, Virginia, United States
Fred Hutchinson Cancer Center, Seattle, Washington, United States